On 03 September 2025, Hoffmann-La Roche conducted a study is to assess the long-term safety and to explore the efficacy of ...

The RESOLUTE phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic ...

AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

Starting next year, citizens aged 56 and 66 will be able to receive pulmonary function tests as part of the National Health ...

A recent study reveals that COPD, or Smokers' Disease, is impacting younger individuals. Doctors in Delhi are observing a ...

“Without appropriate preparation and intervention, patients may experience significant hypoxemia in flight, which can lead to ...

While there has been progress against chronic disease, the U.S. has been backsliding against big killers like heart disease.

A father's exposure to passive smoking as a child may impair the lifelong lung function of his children, putting them at risk of chronic obstructive pulmonary disease.

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

Content by Health System. With Asthma Peak Week typically during the middle of September, now is a great time to learn the ...